{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7"},{"groupId":"OG001","value":"31.5"}]}],"title":"Normal (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4"},{"groupId":"OG001","value":"29.7"}]}],"title":"Mildly restricted (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2"},{"groupId":"OG001","value":"27.0"}]}],"title":"Moderately restricted (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"8.1"}]}],"title":"Severely restricted (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"3.6"}]}],"title":"Immobilized (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"65.8"}]}],"title":"Normal (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0"},{"groupId":"OG001","value":"29.1"}]}],"title":"Mildly restricted (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3"},{"groupId":"OG001","value":"3.8"}]}],"title":"Moderately Restricted (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.3"}]}],"title":"Severely Restricted (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Immobilized (24 weeks) [N=87, 79]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of patients in each category is reported.","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients that received study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (24 weeks overall)","title":"Physician's Assessment of Range of Motion of the Most Affected Joint","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}